The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma

Ying Liu 1,2,3†, Xinhua Wang 4†, Shuang Zeng 1,2, Xiane Zhang 1,2, Jimin Zhao 1,2, Xiaoyan Zhang 1,2, Xinhuan Chen 1,2, Wanjing Yang 1,2, Yili Yang 5, Ziming Dong 1,2, Jingyu Zhu 6, Xin Xu 1,5* and Fang Tian 1,2*

Abstract

Background: We and others have previously shown that the STAT3 signaling pathway is activated in some esophageal squamous cell carcinoma (ESCC) cells and is required for the survival and growth of these primary ESCC-derived xenografts. It has also been shown that the natural polyphenol curcumin is an effective anti-tumor agent.

Methods: Luciferase assay and immunoblotting were performed to examine whether curcumin suppressed STAT3 signaling. CCK-8 assay and xenografts were utilized for analyzing ESCC cell growth in culture and mice. Soft agar assay was carried out to determine the colony formation ability of ESCC cells in the presence or absence of curcumin. Cell death and cell cycle were assessed by In CELL Analyzer 2000. Immunohistochemistry and TUNEL assay were used for detecting apoptosis in ESCC tissues. Molecular docking was performed to evaluate the interaction of curcumin with JAK2. JAK2 activity was assessed using an in vitro cell-free system. HE staining was used to evaluate the ESCC tissues.

Results: The natural polyphenol curcumin inhibited STAT3 phosphorylation rapidly and blocked STAT3-mediated signaling in ESCC cells. It also induced growth arrest and apoptosis in cultured ESCC cells, which were attenuated by enforced expression of STAT3. Furthermore, curcumin preferentially blocked the growth of primary ESCC-derived xenografts that harbored activated STAT3.

Conclusions: Curcumin is able to exert anti-tumor action through inhibiting the STAT3 signaling pathway. Giving its wide use in traditional medicines with low toxicity and few adverse reactions, it is conceivable that curcumin might be further explored as a unique STAT3 inhibitor for anti-cancer therapies.

Keywords: Curcumin, STAT3, Esophageal squamous cell carcinoma, Apoptosis, PDX model

Introduction

Esophageal cancer is the eighth most common malignancy and the sixth most common cause of death from malignancy worldwide [1]. Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancers and accounts for 90% of the cases, whose 5-year survival rate remains less than 30% [2]. The development of ESCC is a multifactorial, multistage and complex biological process involving multiple gene abnormalities [2]. As early as 1850s, Virchow found that inflammation was associated with cancers [3]. Recent studies demonstrated that inflammation could initiate and promote malignant transformation, whereas the genetic and epigenetic changes of malignant cells could generate the inflammatory microenvironment to further support the progression of the tumor [4]. Noteworthily, large number of studies have shown that inflammation-related smoking, alcohol, diet and human papilloma virus (HPV) are all associated closely with the development of ESCC [5].

Curcumin is the main natural polyphenol found in the rhizome of Curcuma longa (turmeric). Many studies showed that curcumin has anti-oxidation, anti-growth, antiarthritic and anti-inflammation actions [6]. In
particular, it has been reported that curcumin induces apoptosis, inhibits cell proliferation and migration in human leukemia, colon, prostate, renal and non-small-cell lung cancer [7–9], suggesting that it might be a novel agent for the prevention and treatment of ESCC.

The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway plays an essential role in immune response, inflammation, and carcinogenesis [10, 11]. Cytokines bind to the receptors and activates JAKs, which in turn phosphorylates STATs. Dimerized and phosphorylated STATs are then translocated into the nucleus to regulate gene expression. Some of these genes are important in cell proliferation and survival, including cyclins and anti-apoptotic proteins [12]. In particular, STAT3 can be activated in many cells by various cytokines and growth factors, such as IL-6 and EGF family members [13, 14]. Noteworthily, constitutive activation of STAT3 has been found in various human cancers, such as breast cancer, prostate cancer, ovarian cancer, hepatocarcinoma, and it has shown that activation of STAT3 contributes to tumor cell growth, metastasis and angiogenesis [15–18]. Thus, targeting STAT3 is regarded as a promising strategy for developing novel therapeutics.

In this study, we used ESCC cell lines and four ESCC PDX (patient-derived xenograft) models to further explore the activity and mechanism of curcumin. We found that the compound downregulates STAT3 signaling by suppressing JAK2 activation, leading to inhibition of cell growth and clony formation, cell cycle arrest and apoptosis. Furthermore, preventive use of curcumin significantly inhibited tumor growth in ESCC patient-derived xenografts. These results indicated that curcumin is an effective agent for the preventive treatment of ESCC harboring constitutively activated STAT3.

Materials and methods
Cells, tissues and chemicals
Esophageal squamous cell carcinoma (ESCC) cell lines EC1, EC9706, KYSE450 and TE13 were provided by Department of Pathophysiology, School of Basic Medicine, Zhengzhou University. All ESCC cell lines were cultured in Dulbecco’s high glucose modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 μg/ml of penicillin, and 100 units/ml of streptomycin at 37 °C with 5% CO2.

The ESCC tumors used for this study were collected from patients enrolled into the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) with consensus, and approved by the Ethics Committee of Zhengzhou University. None of these patients had received preoperative chemotherapy or preoperative radiation therapy. The fresh tumor specimens were collected at the time of surgical resection and prepared for implantation in immunodeficient mice. All specimens were examined by two pathologists to confirm the malignant tissues. All the tissues were inoculated into the mice within 2 h after the operations.

Curcumin, Z-VAD-FMK and AG490 were purchased from Selleck Chemicals (Houston, TX, USA). Annexin V-FITC Apoptosis Detection Kit was purchased from Beyotime Biotechnology (Shanghai, China).

Plasmids construction and gene transfection
The human STAT3 cDNA was cloned into pcDNA3.1 vector with a Myc tag as previously described [19, 20]. A STAT3 luciferase construct (STAT3-Luc) was purchased from Beyotime Biotechnology (Shanghai, China). Plasmids were transiently transfected into EC9706 or TE13 cells by Lipofectamine® 2000 (Invitrogen) according to the manufacturer’s instruction.

Luciferase assay
After transfected with STAT3-Luc or empty vector along with the internal control renilla luciferase by Lipofectamine® 2000 (Invitrogen) for 24 h, TE13 cells were incubated with indicated agents for 12 h, and then stimulated with 50 ng/ml IL-6 (Novoprotein, Shanghai, China) or vehicle control for 20 min. Cells were then prepared for luciferase assay by using Dual-Luciferase® Reporter Assay System (Promega, Madison, WI, USA) as described previously [21, 22].

Immunoblotting analysis
Whole cell lysates were prepared for immunoblotting as described previously [23–25]. Equal amounts of total proteins (30 μg) were subjected to SDS-PAGE, transferred onto nitrocellulose, and immunoblotted with specific antibodies. The primary antibodies against phospho-STAT3 (Tyr705), STAT3, phospho-JAK2 (Tyr1007/1008), JAK2, PARP, MCL1, XIAP, Cox2 and iNOS were purchased from Enzo Life Sciences (Tokyo, Japan). Anti-β-Actin, anti-α-Tublin, anti-mouse IgG and anti-rabbit IgG horse-radish peroxidase conjugated antibodies were purchased from Santa Cruz (Santa Cruz, CA). Anti-Myc antibody was purchased from New England Biolabs (Tokyo, Japan). Anti-GAPDH antibody was purchased from Abgent (Suzhou, China).

Cell survival analysis
ESCC cells were seeded in 96-well plates at a density of 5000 cells/100 μl and cultured overnight at 37 °C with 5% CO2. After treated with indicated concentrations of curcumin for different times, their survival was measured by CCK-8 assay according to the manufacturer’s protocol as described previously [21]. Absorbance was measured at 450 nm wavelength.
Colony forming assay
The colony forming assay was performed as described previously [19]. EC9706 cells (2.4 × 10⁴/well) were exposed to various concentrations of curcumin in BME agar with 10% FBS, and then cultured for 2 or 3 weeks at 37°C in a 5% CO₂ incubator. Colony numbers were determined by a microscope using Image-Pro Plus software (Media Cybernetics, Inc. Rockville, MD).

Cell cycle and apoptosis analyses
Cell cycle and apoptosis analyses were performed as described previously [25, 26]. EC9706 (1 × 10⁵/well) were seeded in 96-well plates and incubated overnight, and treated with different doses of curcumin (0, 4, 8, 12, 16 μM) for 24h. For apoptosis detection, the cells were stained with Hoechst (Beyotime, Shanghai, China) and Annexin V–FITC Kit (Beyotime, Shanghai, China). For cell cycle analysis, the curcumin-treated cells were fixed with 4% paraformaldehyde and stained with DAPI cell cycle analysis, the curcumin-treated cells were fixed with 4% paraformaldehyde and stained with DAPI (Solarbio, Beijing, China) according to the protocol and protected from the light for 20 min at 37°C in a 5% CO₂ incubator. They were analyzed by In CELL Analyzer 2000.

Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted using RNAiso Plus (Takara Bio Group, Japan) according to the manufacturer’s instructions. cDNA was synthesized from equal quantities of total RNA using the PrimeScript™ RT reagent Kit with gDNA Eraser (Takara Bio Group, Japan). To determine the mRNA levels of Cyclin D1, MCL1 and IL-6, qRT-PCR was performed using SYBR Green qPCR Master Mix (Clontech Laboratories, Inc., USA) with Roche LightCycler® 480II real-time PCR system (Roche, Basel, Switzerland). The primers were used as follows: Cyclin D1, forward 5'-AGCTGTCATCCATTACACCGA C-3' and reverse 5'-GAAATCGTGCGGGGTCATTG-3'; MCL1, forward 5'-GGACGGCGGAACAAACT-3' and reverse 5'-ACCATCCAGCCTCTTT-3'; IL-6, forward 5'-GTCAGTGGCCTTCTCCCC-3' and reverse 5'-GCCT CTTCGTGCCTTTCA-3'; GAPDH, forward 5'-GCACCCAGGGCTAGAAC-3' and reverse 5'-TGGTGAAG ACGCCAGTGGA-3'.

Molecular docking
The CDOCKER module of Discovery Studio 3.5 (DS3.5) was used for molecular docking [27]. The crystal structure of JAK2 (PDB entry: 5TQ8) [28] from the RCSB Protein Data Bank (http://www.rcsb.org) was used as the initial structure for molecular docking. The protein structure was prepared with the Prepare Protein tool in DS3.5 and curcumin was sketched by using DS3.5 and then prepared with the Prepare ligands tool. All parameters were set to default. After preparation of the protein and the compound, curcumin was docked into the active site of JAK2, and all parameters were set to default in the docking process of CDOCKER, the protein conformation was fixed and the docked ligand was flexible.

Protein kinase activity assay
The effect of curcumin on purified kinase JAK2 was assessed using the HotSpot technology kit by Reaction Biology Corp. (Malvern, PA, USA) as described previously [19, 29, 30].

Patient-derived xenograft (PDX) study
The human ESCC PDX model was established in female CB17/SCID mice (Vital River, Beijing, China). The primary tumors that had passed 3 generations of implantations were inoculated subcutaneously. When the tumors became palpable, the mice were divided into the following four groups (n = 8/group): (a) control vehicle (80% DMSO + 20% PBS); (b) curcumin prevention and treatment (Mice were in advance intraperitoneally injected with 100 mg/kg curcumin three times a week for half a month before the formal experiment; 100 mg/kg); (c) curcumin (100 mg/kg); (d) 5-FU(5 mg/kg). Curcumin was intraperitoneal injected three times a week for 4 weeks, and 5-FU was injected continuously for the first 3 days. Body weights and tumors were measured twice a week. Tumors' volume was calculated as length × width² × 1/2. The study was approved by the Ethics Committee of First Affiliates Hospital of Zhengzhou University and Basic Medical College of Zhengzhou University.

Immunohistochemistry staining
The paraffin embedding tissue sections were deparaffinized in xylene, treated with a graded series of alcohol and distilled water, and washed thoroughly with TBST. Antigen retrieval was retrieved with 0.01 M sodium citrate (pH 6.0) and microwave boiling. Endogenous peroxidase was blocked by using H₂O₂. After thoroughly washing with TBST, the slides were incubated overnight at 4°C with primary antibodies: p-STAT3, Cox-2 and Caspase-3 diluted in 5% BSA-TBST (1:50) respectively. They were then incubated for 15 min with appropriate dilutions of the secondary antibody at 37°C for 15 min, and were visualized by incubating with DAB for ~5 min. All sections were examined under microscope and analyzed using the HistoQuest 4.0 (TissueGnostics, Austria) as described previously [23].

TUNEL assay
The paraffin embedding tissue sections were deparaffinized in xylene, treated with a graded series of alcohol and distilled water, and washed thoroughly with PBS. They were then incubated with protease K (20 μg/ml in PBS) for 20 min at room temperature, and TUNEL staining was carried out using the in Situ cell death detection kit (KeyGen Biotech Ltd., Nanjing, China) according to the
manufacturer’s instructions. TUNEL-positive cells from five independent fields were counted manually.

**Statistical analysis**

The results were expressed as mean ± standard deviation (S.D), except otherwise stated. The data were analyzed by one-way analysis of variance or Student t test, using SPSS version 17.0 (SPSS, Chicago, USA). *p < 0.05* was considered statistically significant.

**Results**

**Curcumin inhibited the growth of ESCC cells**

Curcumin is a polyphenol derived from the plant *Curcuma longa* and possess significant anti-cancer activities in various studies. To find whether curcumin could affect esophageal squamous cell carcinoma (ESCC) cell survival, we examined the cytotoxicity of curcumin on four ESCC cell lines. As shown in Fig. 1a and b, curcumin significantly suppressed the survival of the ESCC cells tested dose-dependently. EC9706 and TE13 cells were also treated with indicated concentrations of curcumin for different times. As shown in Fig. 1c and d, curcumin also suppressed EC9706 and TE13 cell growth in a time-dependent manner. Furthermore, we examined the effect of curcumin on anchorage-independent growth of EC9706 cells. Colonies formed in the presence of curcumin were significantly reduced dose-dependently (Fig. 1e and f).

![Chemical structure of curcumin](attachment:image1.png)

**Fig. 1** Curcumin inhibited the cell growth of ESCC cells. **a** Chemical structure of curcumin. **b** The cytotoxicity of curcumin in EC1, EC9706, KYSE450 and TE13 cells was evaluated. ESCC cells were treated by indicated concentrations of curcumin for 48 h and then cell viability was measured by CCK-8 assay. **c** and **d** EC9706 cells (c) and TE13 cells (d) were treated with indicated doses of curcumin at indicated time. Cell viability was measured by CCK-8 assay. **e** and **f** Curcumin reduced colony formation of EC9706 cells in a dose-dependent manner. Soft agar assay was performed as described in materials and methods. A representative picture was taken with 200x magnifications (e). Colonies were counted under a microscope and the data was shown as mean±SD from triplicate experiments (f). *p < 0.05, **p < 0.01
Curcumin promoted cell cycle arrest and induced cell apoptosis in ESCC cells

To further understand the inhibitory action of curcumin on the growth of ESCC cells, we examined the effects of curcumin on cell cycle progression and apoptosis. In the presence of curcumin, there was a significantly increase of EC9706 and TE13 cells arrested at the S phase (Fig. 2a and b). The treatment of EC9706 and TE13 cells with curcumin also led to a markedly increased numbers of apoptotic cells (Fig. 2c). We then evaluated the statuses of caspase substrate PARP in these cells by immunoblotting. As shown in Fig. 2d, curcumin treatment induced the cleavage of PARP dose-dependently in both of EC9706 and TE13 cells. Immunoblotting also showed that the anti-apoptotic proteins MCL1 and XIAP were significantly downregulated by curcumin treatment (Fig. 2d). The curcumin-induced apoptosis was also significantly blocked by Z-VAD-FMK, a potent caspase inhibitor (Fig. 2e). Interestingly, curcumin-induced cell death was significantly attenuated when EC9706 cells were transfected with STAT3-expressing construct (Fig. 2f). Moreover, treatment with IL-6, a STAT3 activating cytokine, substantially inhibited the effect of curcumin on ESCC cell survival (Fig. 2g). In contrast, the presence of AG490, a STAT3 inhibitor, markedly enhanced the effect of curcumin on inducing ESCC cell death (Fig. 2h). These data indicated that curcumin induced apoptosis in ESCC cells, which was affected by STAT3 activation.
Curcumin inhibited STAT3 activation by suppressing JAK2 phosphorylation in ESCC cells

The involvement of STAT3 in curcumin-induced apoptosis of ESCC cells propelled us to further examine STAT3 function in these cells. Like the STAT3 inhibitor, curcumin inhibited both spontaneous and IL6-induced STAT3-driven luciferase activities dose-dependently (Fig. 3a). Immunoblotting analysis showed that curcumin decreased the constitutive levels of p-STAT3, but not the total STAT3 in both EC9706 and TE13 cells dose-dependently (Fig. 3b) and time-dependently (Fig. 3c). Moreover, pre-treatment with curcumin blocked IL-6-induced STAT3 phosphorylation in both of EC9706 and TE13 cells (Fig. 3d). To further assess the effect of curcumin on STAT3 activity, the expression levels of several STAT3 target genes were measured by qRT-PCR. As shown in Fig. 3e, the mRNA levels of Cyclin D1, MCL1 and IL-6 were all significantly downregulated by curcumin treatment. Therefore, curcumin effectively suppressed STAT3 phosphorylation and STAT3-mediated transactivation in ESCC cells.

As JAK2 is an important upstream kinase that phosphorylates STAT3, we analyzed its interaction with curcumin by computer modeling. As shown in Fig. 4a, curcumin was docked nicely into the binding pocket of JAK2. Glu898, Val911, Tyr931, Leu932, Ser936, Asp939 and Asp994 of JAK2 formed strong interactions with curcumin. Among them, Val911, Tyr931 and Ser936 may interact hydrophobically with curcumin, whereas Glu898, Leu932, Asp939 and Asp994 are able to form H-bonds with curcumin. Leu932 in particular can form two H-bonds with curcumin (Fig. 4a). It is conceivable that these H-bonds played a key role in preventing the escape of curcumin from the binding site. We also examined the

![Fig. 3](image-url)
effect of curcumin on JAK2 experimentally. As shown in Fig. 4b, curcumin markedly inhibited IL6-induced JAK2 phosphorylation in both EC9706 and TE13 cells, similar to its inhibition on STAT3 (Fig. 3d). And the constitutive phosphorylation of JAK2 was also suppressed by curcumin in EC9706 and TE13 cells (Fig. 4c). Furthermore, in the cell-free enzymatic assay, curcumin inhibited JAK2 activity with an IC50 ~ 8 μM (Fig. 4d). Therefore, it is likely that curcumin blocked STAT3 signaling in ESCC cells by inhibiting JAK2 activity.

Curcumin suppressed tumor growth in ESCC PDX models
Patient-derived xenograft (PDX) has been proposed as a preferred model to evaluate the potential therapeutic effect of curcumin, we established PDXs in SCID mice from primary tumors EG2, EG37, EG60 and EG84. The clinical information of patients EG2, EG37, EG60, and EG84 was summarized in Table 1. Mice with the xenografts were treated with the vehicle, 5-FU, curcumin, or curcumin prevention (mice were in advance intraperitoneally injected with 100 mg/kg curcumin three times a week for half a month before the formal experiment). As shown in Fig. 5a-d, curcumin markedly inhibited the growth of xenografts derived from EG2, EG37, EG60 and EG84. After sacrificed by the end of the treatment, tumor weight from mice received curcumin and curcumin prevention was decreased significantly compared to the control group. Furthermore, curcumin prevented the increase of tumor weight and improved the survival rate of mice. Therefore, curcumin can effectively inhibit the growth of ESCC xenografts in vivo.

Table 1 The clinical pathological features of PDXs

| Number | Gender | Age | Tumor Type                        | TNM Staging | Differentiation |
|--------|--------|-----|-----------------------------------|-------------|----------------|
| EG2    | male   | 64  | oesophagus squamous cell carcinoma| T2N0M0      | II             |
| EG37   | male   | 69  | oesophagus squamous cell carcinoma| T3N0M0      | II             |
| EG60   | male   | 60  | oesophagus squamous cell carcinoma| T1N0M0      | II             |
| EG84   | male   | 60  | oesophagus squamous cell carcinoma| T4N0M0      | II             |
significantly lower than that from mice given the vehicle (Fig. 5e-h). As a positive control, 5-FU also had notable effect in inhibiting the growth of the xenografts under these experimental conditions. Noteworthily, curcumin prevention group had the most significant inhibition of tumor growth (Fig. 5a-d). The representative photos of the excised tumors from EG60 and EG84 were shown in Fig. 5i and j. These results indicated that curcumin inhibited ESCC tumor growth in the PDX models.

**Curcumin suppressed STAT3 phosphorylation and induced apoptosis in ESCC PDX models**

To further evaluate the effect of curcumin on ESCC tumors in PDX models, excised tumor tissues were prepared for immunoblotting analysis. As shown in Fig. 6a, the tumors in animals administrated by curcumin or curcumin prevention contained lower levels of phosphorylated STAT3 than those from vehicle-treated mice. HE staining, TUNEL assay, and IHC analysis were then performed. As shown in Fig. 6b, HE staining indicated that there was less cell growth in tumors from mice received curcumin or curcumin prevention. The TUNEL assay revealed that there were increased apoptotic cells in curcumin-treated tumors (Fig. 6c and d). The IHC analysis with specific antibodies showed that the levels of phosphorylated STAT3 and its target protein Cox2 were markedly decreased in tumors treated with curcumin or curcumin prevention, whereas caspase 3 staining was significantly increased in these tumors (Fig. 6e-h). These data indicated that curcumin or curcumin prevention inhibited PDX tumor growth through inhibiting STAT3 signaling and inducing apoptosis.

**Discussion**

STAT3 can be activated by a variety of cytokines including IL-6, IL-10 and TNFα [36]. Constitutive activation of STATs has been found in a number of tumors, including lymphoma, breast cancer, colorectal cancer and prostate cancer [32–35]. Many of the physical, chemical and biological stimuli that induce inflammation, including ultraviolet, reflux gastric juice, and endotoxin, can also activate STAT3 by different mechanisms [37]. Moreover, genes induced by STAT3 can also promote the development of inflammation, forming the positive feedback
mechanisms of inflammation development [38]. It has been shown that STAT3 is an important regulator for many genes involved in survival, invasion, cycling, and apoptosis of tumor cells [39, 40]. It has been also demonstrated that down-regulation or inhibition of STAT3 signaling can suppress tumor growth in vitro and in animal models [41]. Thus, STAT3 appears to be a desirable drug target for cancer therapy.

Curcumin is a yellow pigment commonly used as a dietary spice and as a component of traditional medicine in China and India, primarily for anti-neoplasms and anti-inflammation [42]. Although the compound has not been developed as a drug in modern medicine, it is conceivable that identification of proper biomarkers, such as activated STAT3, might significantly promote its clinical trials and potential applications in the near future. Whasun Lim et al. [43] found that curcumin suppressed proliferation and apoptosis on human placental choriocarcinoma. Gallardo et al. [44] also showed that curcumin inhibited invasive capabilities of breast cancer cells. Our previous study demonstrated that NF-κB signaling pathway was activated in a subgroup of esophageal squamous cell carcinoma (ESCC), and curcumin inhibited ESCC cell proliferation and induced apoptosis [45–47]. Therefore, exploring the effect of curcumin on STAT3 signaling may provide novel therapeutic strategies for ESCC.

In this study, we found that curcumin inhibited the growth of different ESCC cell lines (Fig. 1). It induced cell cycle arrest at S phase and promoted apoptosis dose-dependently in EC9706 and TE13 cells (Fig. 2). Both constitutive and IL6-induced STAT3 activations were strongly inhibited by curcumin treatment in EC9706 and TE13 cells (Fig. 3). Noteworthily, Cox2, which catalyzes the conversion of arachidonic acid to prostaglandins, is inducible by many cytokines in an STAT3-dependent manner [48, 49]. It is highly expressed in many premalignant and malignant lesions, including nasopharyngeal carcinoma, lung cancer, breast cancer [50–52]. A number of studies indicated that Cox2 plays an important role in
apoptosis, angiogenesis and tumor invasion [53]. In the present study, we found that the expression of Cox2 was markedly inhibited by curcumin in PDX of ESCC (Fig. 6e-h). We also found that overexpression and activation of STAT3 all decreased the sensitivity of ESCC cells to curcumin (Fig. 2e-g), and the STAT3 inhibition enhanced curcumin-induced ESCC cell death (Fig. 2h). Thus, the effect of curcumin on ESCC cells requires the inhibition of STAT3-mediated signaling.

In the animal experiments, we evaluated the potential therapeutic as well as chemopreventive action of curcumin. Interestingly, as shown in Fig. 5a-c, preventive administration of curcumin was markedly more effective in inhibiting PDXs derived from EG2, EG37 and EG60 than giving curcumin only after inoculation of tumors. In these PDXs, curcumin inhibited STAT3 phosphorylation and the expression of STAT3-regulated Cox2 (Fig. 6e-h). Furthermore, TUNEL assay revealed that apoptosis in the tumor tissues were significantly increased by curcumin treatment (Fig. 6c and d). Taken together, our data indicated that curcumin inhibited JAK2 and blocked the activation of STAT3, leading to decreased expression of STAT3-regulated genes and increased apoptosis in ESCC cells and primary tumors. Therefore, the natural product might be used as an effective chemoprevent agent for ESCC.

**Conclusion**

STAT3 signaling is an important mechanism for the development of at least certain ESCC. In this study, we showed that curcumin may inhibit JAK2 and blocked STAT3 signaling pathway, resulting in growth inhibition and apoptosis of these ESCC cells. Therefore, STAT3 system appears to be an effective target in ESCC and curcumin is able to target the system to prevent and treat ESCC.

**Abbreviations**

CCK-8: Cell Counting Kit-8; ESCC: Esophageal squamous cell carcinomas; HE staining: Hematoxylin-eosin staining; IHC: Immunohistochemistry staining; IL-10: Interleukin-10; IL-6: Interleukin-6; JAK2: Janus kinase 2; PDX: Patient-derived xenograft; qRT-PCR: Quantitative real-time polymerase chain reaction; SDS-PAGE: Sodium dodecylsulfate polyacrylamide gel electrophoresis; STAT3: Signal transducer and activator of transcription 3; TNFα: Tumor necrosis factor alpha; TUNEL: Terminal deoxynucleotidyl transferase(TdT)-mediated dUTP nick end labeling

**Acknowledgements**

Not applicable.

**Funding**

This work was supported by the National Natural Sciences Foundation of China (U1304813), the Science Foundation of the Henan Province of China (1721013023), Young Teacher Special Fund of Zhengzhou University (1421328055), Foundation and Frontier Technology Research Project in Henan Province (142300410325) and Natural Science Foundation of Jiangsu Province (BK20171231).

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Authors’ contributions**

YL, XW, SZ, XiaZ, JZ, XiaoZ, XC, WY, ZD, JZ and XX performed the experiments. YY, XX and FT wrote and edited the manuscript. XX and FT designed the research project. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the Review Board and Ethical Committee of Zhengzhou University.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, People’s Republic of China. 2Department of Histology and Embryology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, People’s Republic of China. 3School of Medicine and Pharmaceutics, Jiangnan University, Wuxi, Jiangsu 214000, People’s Republic of China. 4Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, People’s Republic of China. 5School of Medicine and Pharmaceutics, Jiangnan University, Wuxi, Jiangsu 214000, People’s Republic of China. 6Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, People’s Republic of China. 7School of Medicine and Pharmaceutics, Jiangnan University, Wuxi, Jiangsu 214000, People’s Republic of China. 8Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, People’s Republic of China. 9School of Medicine and Pharmaceutics, Jiangnan University, Wuxi, Jiangsu 214000, People’s Republic of China.

**Received:** 28 June 2018 **Accepted:** 13 November 2018

**Published online:** 05 December 2018

**References**

1. Wong MCS, Hamilton W, Whiteman DC, Jiang JY, Qiao Y, Fung FDH, Wang HX, Chiu PWY, Ng EKW, Wu JCY, Yu J, Chan FKL, Sung JYY. Global incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries. Sci Rep. 2018;8:4522.

2. Zhang W, Luo Y, Wang X, Han G, Wang P, Yuan W, Dai SB. Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy. Cancer Manag Res. 2018;10:2675–82.

3. Morrison WB. Inflammation and cancer: a comparative view. J Vet Intern Med. 2012;26:18–31.

4. Nissinen L, Farschchian M, Rihlma P, Kahari VM. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. Cell Tissue Res. 2016;365:691–702.

5. Sundaram GM, Veera Bramhachari P. Molecular interplay of pro-inflammatory transcription factors and non-coding RNAs in esophageal squamous cell carcinoma. Tumor Biol. 2017;39:1042831770570.

6. Shakeri A, Cicero AFG, Panahi Y, Mchaieji M, Sahbekar A. Curcumin: a naturally occurring autophagy modulator. J Cell Physiol. 2018. https://doi.org/10.1002/jcp.27404.

7. Mu J, Wang X, Dong L, Sun P. Curcumin derivative L6H6 inhibits proliferation and invasion of gastric cancer cell line BGC-823. J Cell Biochem. 2018. https://doi.org/10.1002/jcb.27542.

8. Zang H, Xu W, Li B, Zhang K, Wu Y, Xu H, Wang J, Zhang J, Fan R, Wei J. Curcumin promotes cell cycle arrest and inhibits survival of human renal Cancer cells by negative modulation of the P38/AKT signaling pathway. Cell Biochem Biophys. 2015;73:681–6.

9. Lev-Ari S, Starr A, Katzburg S, Berkovich L, Rimmon A, Ben-Yosef R, Vexler A, Ron I, Earon G. Curcumin induces apoptosis and inhibits growth of orthotopic human non-small cell lung cancer xenografts. J Nutr Biochem. 2014;25:843–50.

10. Kleppe M, Kwak M, Kopplik P, Rieker M, Keller M, Bastian L, Hrick T, Bhagwat N, McKenney AS, Papaleo E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL. JAK-STAT
pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5:316–31.

11. Garg N, Bahikshian D, Venugopal C, Mahendram S, Rosa DA, Vijayakumar T, Manoranjan B, Hettiaratchi P, Maclean N, Delaney KH, Kwiecien JM, Arpin CC, Lai PS, Gomez-Baqui RF, Ali AM, de Araujo ED, Ajani OA, Hassell JA, Gunnin PT, Singh SK. CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence. Oncogene. 2016;36:606–17.

12. Arora L, Kumar AP, Arfuso F, Chng JW, Sethi G. The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies. Cancers. (Basel). 2018;10:e327.

13. Notarangelo T, Sisinni L, Trino S, Calice G, Simeon V, Landriscina M. IL-6/STAT3 axis mediates resistance to BFAF inhibitors in thyroid cancer cells. Cancer Lett. 2018;433:147–55.

14. Ta NL, Chakabandhu K, Huault S, Hueber AO. The tyrosine phosphorylated pro-survival form of Fas intensifies the EGFR-induced signal in colorectal cancer cells through the nuclear EGRF/STAT3-mediated pathway. Sci Rep. 2018;8:12424.

15. Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014;44:403–11.

16. Han Z, Wang X, Ma L, Chen L, Xiao M, Huang L, Cao Y, Bai J, Ma D, Zhou J, Hong Z. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget. 2014;5:8416–28.

17. McCarran GA, Naidu S, Rath KS, Bid HK, Tierney BJ, Suarez A, VARADHARAJ S, Zhang J, Hidek H, Houghton P, Kuppummary P, Chien DE, Selvendiran K. Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. Oncoscience. 2014;1:216–28.

18. Zhang J, Du J, Liu Q, Zhang Y. Down-regulation of STAT3 expression using vector-based RNA interference promotes apoptosis in Hepatocarcinoma cells. Artif Cells Nanomed Biotechnol. 2016;44:1201–5.

19. Xu X, Han K, Zhu J, Mao H, Lin X, Zhang Z, Cao B, Zeng Y, Mao X. An inhibitor of cholesterol absorption displays anti-melanoma activity by targeting the JAK2-STAT3 signaling pathway. Oncotarget. 2016;7:55359–90.

20. Chen G, Xu X, Tong J, Han K, Zhang Z, Tang J, Li S, Yang C, Li G, Cao B, Zhou H, Wu D, Moran MF, Mao X. Ubiquitination of the transcription factor c-MAF is mediated by multiple lysine residues. Int J Biochem Cell Biol. 2014;57:157–66.

21. Xu X, Wang J, Han K, Li X, Xu F, Yang Y. The anti-malarial melofloxacin inhibits NF-kappaB signaling and inhibits apoptosis in colorectal cancer cells. Cancer Sci. 2018;109:1220–9.

22. Xu X, Han K, Tong X, Zeng Y, Lin X, Zhao Y, Zhang Z, Cao B, Wu D, Mao X. The ring finger protein RNF6 induces leukemia cell proliferation as a direct target of pre-B-acute leukemia Homeobox 1. J Biol Chem. 2016;291:9617–28.

23. Zeng Y, Xu X, Wang S, Zhang Z, Lu Y, Han K, Cao B, Mao X. Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha. Oncotarget. 2017;8:20103–12.

24. Han K, Xu X, Xu Z, Chen G, Zeng Y, Zhang Z, Cao B, Kong Y, Tang X, Mao X, SC6δ, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway. Sci Rep. 2015;5:12809.

25. Han K, Xu X, Chen G, Zeng Y, Zhu J, Lu X, Zhang Z, Cao B, Liu Z, Mao X. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. J Hematol Oncol. 2014;7:9.

26. Zhang J, Hidek H, Houghton P, Kuppumarry P, Chien DE, Selvendiran K. Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. Oncoscience. 2014;1:216–28.

27. Nitschinsk K, Idris A, McMillan N. Patient derived xenografts as models for drug testing in cancer. J Hematol Oncol. 2016;8:12424.

28. Morales EE, Aggarwal BB, Kamat AM. Natural compounds targeting STAT3 pathway. J Cell Physiol. 2015;230:2069–79.

29. Jiang X, Zhang H, Yang Z, Zhang J, Han L, Wang L, Cao B, Liu Z. Transcription factor forkhead box B1, a novel inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway. Oncotarget. 2016;7:60263–72.

30. Wang H, Xie H, Wu J, Wang Y, Li C, He X, Chen Y, Li X, Cao B, Liu Z. SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma through the structural optimization. J Hematol Oncol. 2014;7:9.

31. Nitschinsk K, Idris A, McMillan N. Patient derived xenografts as models for drug testing in cancer. J Hematol Oncol. 2016;8:12424.

32. Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Klardjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Heihlmann R, Maria Vannucchi
A, Cervantes F, Silver RT, Barbui T. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30:1018–24.

49. Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB. Signal transducer and activator of transcription 3, mediated remodeling of the tumor microenvironment results in enhanced tumor drug delivery in a mouse model of pancreatic Cancer. Gastroenterology. 2015;149:1932–1943.e9.

50. Gadgeel SM. Cyclooxygenase 2 inhibition in patients with non-small cell lung cancer: is this still a valid target for therapy? Cancer. 2015;121:3197–200.

51. Li ZL, Ye SB, OuYing HY, Zhang H, Chen YS, He J, Chen QY, Qian CN, Zhang XS, Cui J, Zeng YY, Li J. COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. Oncoimmunology. 2015;4:e1044712.

52. Li A, Chen P, Leng Y, Kang J. Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway. Oncogene. 2018. https://doi.org/10.1038/s41388-018-0379-9.

53. Basudhar D, Bharadwaj G, Somasundaram V, Cheng RYS, Ridnour LA, Fujita M, Lockett SJ, Anderson SK, McVicar DW, Wink DA. Understanding the tumour microenvironment communication network from a NOS2/COX2 perspective. Br J Pharmacol. 2018. https://doi.org/10.1111/bph.14488.